ArticleThe Lancet regional health. Western Pacific2025

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Jinqi Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.